Hyprview, founded in 2022 in Caen, is building a proprietary optical imaging platform designed to generate predictive insights for oncology. The technology aims to help clinicians anticipate cancer progression and treatment response by combining high-resolution imaging with data analysis. With its current funding, the company plans to multiply proof-of-concept studies to validate the clinical utility of its platform across multiple cancer types. Management’s near-term objective is to establish a robust set of clinical data that can support regulatory submissions and commercial partnerships. Financially, Hyprview has secured €1.4 million to date, combining equity and non-dilutive instruments. This capital is earmarked for expanding R&D, running additional clinical validations, and strengthening intellectual property around its imaging technology.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2025